Top 50 Biotechnology Startup Investors in Sweden in September 2025

Whether you are an investor or entrepreneur, partner with Sciety to achieve impactful returns and elevate your life science business in the Nordics.

We are a leading tech investor & venture builder in the Nordics. Taking deep tech from lab to market.WELCOMEINVESTMENTS

Almi Invest is Sweden’s most active early-stage venture capital firm, investing in scalable startups across Sustainability, Industry, Tech, and Life Science.We invest from pre-seed to Series A, always co-investing with independent private investors to accelerate innovation and long-term success. Our portfolio spans sustainable solutions,industrial innovation, deep tech, SaaS, and life science, supporting startups that drive economic and environmental progress.With €430 million under management and over 1,000 investments since 2009, we have backed leading companies like MIPS, Tobii, and Neo4j, with notable exits to Google, Apple, Microsoft, and Qlik.Beyond capital, we offer engaged ownership, providing strategic guidance, active board participation, and access to an extensive investor network.Almi Invest is part of the Almi Group and is funded by the European Regional Development Fund, Almi AB, and regional partners.

Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.

Welcome to Navigare Ventures. We invest in transformational early-stage companies at the frontier of science and technology.

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.

We are a venture capital fund investigating in Start-Ups solving the worlds biggest problems while building massive businesses.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Since 2005, Inventure has backed over 90 companies including Wolt, Swappie, Jobbatical, aiMotive, and more.

We help great minds unleash their full potential!

Voima Ventures’ mission is to solve major global problems by combining science, entrepreneurship, and value adding capital. They shed light on the ideas and technology which require time and courage to build. Industry domains include bio and new materials, medical technologies and life sciences, imaging and optics, IoT and electronics, robotics,software & ICT and AI. In addition, Voima Ventures has invested in more than 30 deep tech startups, including companies like Solar Foods, Infinited Fiber Company, and Dispelix. Cornerstone investors are VTT Technical Research Centre of Finland and European Investment Fund (EIF), backed by Finnish private and institutional investors.

Partnerinvest Norr is a private equity firm specialized in software, security, and biometrics sectors. Partnerinvest Övre Norrland AB is a venture capital firms that seeks to invest in limited companies which have are in the expansion phase.

Crowberry Capital invests at seed and early stage in emerging technology ventures in the Nordics. Our mission is to back people that are good for companies and build companies that are good for people. We have a strong follow-through philosophy and commit to putting your company first.

FARO is an Argentina company over 10 years of experience in the development and operation of integrated projects in the agribusiness sector. All projects FARO own position it as a reference and leader both locally and internationally.Among his various projects, FARO operates the largest tree planting pecan nut Latin America, with projection tobecome the largest southern hemisphere and one of the largest in the world. This project is structured under different vehicles, including Alto Pecan stands, the first real estate development of nautical fields planted with pecan nut Latin America, located in Villa Paranacito, Entre Ríos . Another project is AgroConsortium, productive trust for the production and marketing of cereals and oilseeds in leased farms located in different productive areas in Argentina and potentially in the region. Finally, thanks to the expertise acquired in agribusiness, FARO developed his own business model for productive land conversion. Its aim is to position rural properties whose productive potential is not reflected in the price and complement the cycle with the economic use of land in intensive production, short and medium term.Since 2006, the Investor Group is a strategic partner OMBU FARO for all investment portfolios development ventures related to agribusiness, that focus on supply both local and international markets.

Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion

EIR Ventures is a new Life Science Venture Group in the Nordics.

We deploy early stage capital to fuel the growth of need-driven health technology companies.

LIU invests in companies that are based on projects and ideas from Linköping University. LIU Invest is focused on investments in early phases. Investments are typically 250 000, but can be doubled by an additional investment.

Segulah Medical Acceleration is a Scandinavia-based investment company focusing on innovative medical technology companies in Europe.

LU Holding is a Lund University’s investment company.

SEB Venture Capital is a Fintech investor that helps entrepreneurs and innovators launch and grow profitable businesses. They primarily serve as a strategic corporate venture focused on Fintech investments, with the option of partnering with SEB. They are also on the hunt for game-changing inventive solutions to new technologies that will make thefinancial industry smarter, safer, and more environmentally responsible, as well as more user-friendly. They also function as an evergreen fund, giving them the flexibility and staying strength to focus on long-term wealth development depending on what is best for the firm and its shareholders.

Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine.

Länsförsäkringar is a Swedish group of public insurance companies.

Andreas is working on a service that will connect people, time and places on the web. He also works as an independent consultant helping other startups with product strategy, technical infrastructure, scalability and recruiting as well as financial companies (venture capital and private equity) with technical due diligence and in other advisorroles.He was CTO at Spotify from the launch of the company in August 2006 until November 2009. Before that he worked at Stardoll as an engineer and project manager.

Noaber Ventures invests in initiatives that bring social transformations using information technology.

I Love Lund is a venture capital firm.The firm seeks opportunities to invest in pre-seed rounds

Annexstruktur is a venture capital firm that provides investments to companies.

We partner with founders to transform unseen scientific discoveries into future breakthroughs, jointly moving businesses, people, and the world forward.

Klimatet Invest is to create long-term value growth by investing relatively early in idea companies with good growth potential in cleantech and at the same time contributing to a more sustainable society.

Pan-european early-stage deep-tech VC

Investinor invests in Norwegian based, high potential companies that are internationally oriented and in the phases ranging from early growth to expansion. The company has BNOK 4.2 ($500 m) under management and focus on companies within the internet, software, semiconductors, energy, cleantech, marine and life sciences sectors.

LifeArc Ventures a self-funding medical research charity that invests in Seed and Series-A stage Biotech and Healthtech companies.

Jens Mogensen is an Angel Investor.

Inter IKEA Group's aim is to secure continuous improvement, development, expansion and a long life of the franchising operation.

ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences

Porte Monnaie is an early and active investor for startup companies and passive investors in listed companies with growth potential. Porte-Monnaie's mission is to invest in Swedish companies.

Nxt2b is a venture capital company focused on investments in healthcare, pharmaceuticals companies, and medical devices.

Landegren Gene Technology

JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson Innovation. Learn more about our equity investment strategy.

Falkenbergs Sparbanks Foundation

Kale United offers a portfolio of over 75+ plant-based game changers

Fåhraeus Startup and Growth is a venture capital fund that invests early in life science and tech companies.

GOBIA Enterprises is owned by Jan G Smith who has been active in the pharmaceutical industry.

KTH Holding is a state-owned limited company managed by KTH's University Board. It invests in promising startup companies that are based on research or teaching at KTH, with the aim of supporting commercialization and making it easier for new science to benefit society.

The European Investment Bank (EIB) offers lending, borrowing, and treasury services primarily within the European Union. It provides project loans for public and private sectors, loans to banks and intermediaries, structured finance products, guarantees, and securitization instruments for debts. Additionally, EIB offers equity and fund investmentproducts, including infrastructure and environmental funds, as well as venture capital funds. EIB also supports microfinance and risk-sharing finance for research and innovation and provides technical expertise for sustainable energy projects. Its services include infrastructure advisory, urban development support, guarantees for transport infrastructure, and funding for public-private partnerships and small- to medium-sized enterprises. The bank serves various sectors, including transportation, energy, health, education, and agriculture.

Simon Fredriksson is the Co-Founder and CEO of Pixelgen Technologies. He attended Stanford University School of Medicine in 2003.

TPG Growth was founded in 2007 to specialize in growth equity and middle-market buyout opportunities. Taking a long-term and hands-on approach to partnership, we identify unique companies across the U.S., Europe, Africa, and Asia and help them achieve their full potential. We can assist at all stages of a company’s growth, from its inception to itsinternational expansion, by drawing on our geography-specific experience and expert global operational resources from the TPG platforms. TPG Growth manages more than $7 billion in assets across a variety of sectors including media, technology, and industrials.

We are investing in #FutureFood. Nordic FoodTech VC is the first fund in the Nordics investing explicitly in the future of food

Almi Invest GreenTech is a venture capital company and an active start-up investor.